Fundraising Fox迪哲医药 (Dizal Pharma)
3 known investors
Find your way into 迪哲医药 (Dizal Pharma)
Sign up to find every way you can get introduced to 迪哲医药 (Dizal Pharma)
- Your email: who you already know at 迪哲医药 (Dizal Pharma), and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the 迪哲医药 (Dizal Pharma) team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
Investors · 3
Related companies · 3
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ZentalisZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies working in the same space as 迪哲医药 (Dizal Pharma).
Frequently asked questions
- What does 迪哲医药 (Dizal Pharma) do?
- Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
- Who are 迪哲医药 (Dizal Pharma)'s investors?
- 迪哲医药 (Dizal Pharma)'s investors include HongShan Capital Group, LAV, Lilly Asia Ventures.